АССОЦИАЦИЯ ФЛЕБОЛОГОВ РОССИИ

Уважаемые коллеги есть ли у вас опыт применения пропионил - L -карнитина при клаудикации? Какие ваши мнения по данному препарату?

А какое отношение имеет L-карнитин к хромоте? И почему Вы считаете, что у нас может быть опыт использования БАД в лечении хромоты? Вы нас ни с кем не спутали? В интернете полно мест для подобных вопросов!

Насколько мне известно L-карнитин и пропионил-L-карнитин отноятся к специфическим модуляторам метаболизма миокарда, а если точнее, то к модуляторам митохондриального ацетил-КоА.
А что есть лекарственные формы этих веществ?
С уважением,
М.Кудыкин

Rech' idet imenno o Propionyl -L -carnitine
Da deystvitel'no l-carnitine primenyalsya v cardiologii, a acetyl - L carnitin uluchshaet spermatogenez.
V to vremya, kak pokazyvayut rezul'taty randomizirovannyx multicentrovyx issledovaniy, Propionyl -L - carnitine dostoverno uvelichivaet distanciyu bezbolevoy xod'by pri premezhayusheysya xromote.

Понятно.
А название афицинальное есть. Может быть есть возможность ссылку скиньте по мультицентровым исследованиям. Интересно.
С уважением,
М.Кудыкин

Naschet nazvaniya ne znayu no ssylok po dannoy teme ne malo, vot naprimer abstract

Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication.Hiatt WR, Regensteiner JG, Creager MA, Hirsch AT, Cooke JP, Olin JW, Gorbunov GN, Isner J, Lukjanov YV, Tsitsiashvili MS, Zabelskaya TF, Amato A.
Department of Medicine, Section of Vascular Medicine, Divisions of Geriatrics and Cardiology, University of Colorado Health Sciences Center, Denver 80203, USA.

PURPOSE: We tested the hypothesis that propionyl-L-carnitine would improve peak walking time in patients with claudication. Secondary aims of the study were to evaluate the effects of propionyl-L-carnitine on claudication onset time, functional status, and safety. SUBJECTS AND METHODS: In this double-blind, randomized, placebo-controlled trial, 155 patients with disabling claudication from the United States (n = 72) or Russia (n = 83) received either placebo or propionyl-L-carnitine (2g/day orally) for 6 months. Subjects were evaluated at baseline and 3 and 6 months after randomization with a graded treadmill protocol at a constant speed of 2 miles per hour, beginning at 0% grade, with increments in the grade of 2% every 2 minutes until maximal symptoms of claudication forced cessation of exercise. Questionnaires were used to determine changes in functional status. RESULTS: At baseline, peak walking time was 331 +/- 171 seconds in the placebo group and 331 +/- 187 seconds in the propionyl-L-carnitine group. After 6 months of treatment, subjects randomly assigned to propionyl-L-carnitine increased their peak walking time by 162 +/- 222 seconds (a 54% increase) as compared with an improvement of 75 +/- 191 seconds (a 25% increase) for those on placebo (P <0.001). Similar improvements were observed for claudication onset time. Propionyl-L-carnitine treatment significantly improved walking distance and walking speed (by the Walking Impairment Questionnaire), and enhanced physical role functioning, reduced bodily pain, and resulted in a better health transition score (by the Medical Outcome Study SF-36 Questionnaire). The incidence of adverse events and study discontinuations were similar in the two treatment groups. CONCLUSIONS: Propionyl-L-carnitine safely improved treadmill exercise performance and enhanced functional status in patients with claudication.